23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

German Merck divests its US CDMO business

German pharma group Merck KGaA is selling its US CDMO business to Swiss biotech group Lonza. The deal covers five manufacturing sites in the US and around 1,100 employees.
Advertisement

The acquisition will more than double Lonza’s US operations, bringing its total to nine sites and more than 6,000 employees. Lonza is one of the world’s leading contract development and manufacturing organisations (CDMOs).

The sites changing hands are located in Carlsbad, California; Madison and Verona, Wisconsin; St Louis, Missouri; and Indianapolis, Indiana.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.063|